Nanjing Well Pharmaceutical GroupLtd 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Renrong Wu

최고 경영자

CN¥990.7k

총 보상

CEO 급여 비율	n/a
CEO 임기	4.6yrs
CEO 소유권	13.7%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	4.6yrs

최근 관리 업데이트

Recent updates

CEO

Renrong Wu (61 yo)

4.6yrs

테뉴어

CN¥990,700

보상

Mr. Renrong Wu is Chairman, Director & CEO of Nanjing Well Pharmaceutical Group Co.,Ltd. from April 08, 2020. He joined the Nanjing Well Pharmaceutical Group Co.,Ltd.in February 2000.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Renrong Wu	Chairman & CEO	4.6yrs	CN¥990.70k	13.68% CN¥ 445.8m
Zhengsong Gao	Director	4.6yrs	CN¥825.60k	10.42% CN¥ 339.7m
Xinguo Chen	Director & VP	4.6yrs	CN¥825.60k	10.42% CN¥ 339.7m
Yamei Guan	Independent Director	1.5yrs	CN¥49.70k	데이터 없음
Rongwen Wu	Chairman of the Supervisory Board	4.6yrs	데이터 없음	2.2% CN¥ 71.7m

4.6yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: 603351 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.

Nanjing Well Pharmaceutical GroupLtd 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Nanjing Well Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 17, 2024

No independent directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 3Q 2023)

Investor sentiment improves as stock rises 18%

Nanjing Well Pharmaceutical Group Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Second quarter 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.19 in 2Q 2023)

Nanjing Well Pharmaceutical Group Co.,Ltd. to Report First Half, 2024 Results on Aug 20, 2024

Dividend increased to CN¥0.30

Nanjing Well Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 17, 2024

Nanjing Well Pharmaceutical Group Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment deteriorates as stock falls 16%

Nanjing Well Pharmaceutical Group Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.14 in 3Q 2022)

Nanjing Well Pharmaceutical Group Co.,Ltd. (SHSE:603351) completed the acquisition of13% stake in Nanjing Xingwei Biotechnology Co., Ltd. from Wu Renrong, Gao Zhengsong, Chen Xinguo, Tang Qunsong, Shen Jiusi, Wu Rongwen, Hong Shilin, Zou Jianguo, Wang Fuqiu and Zhou Chong.

Nanjing Well Pharmaceutical Group Co.,Ltd. to Report First Half, 2023 Results on Aug 29, 2023

First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.23 in 1Q 2022)

Investor sentiment deteriorated over the past week

No independent directors

Third quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.21 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.23 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 1Q 2021)

Full year 2021 earnings released: EPS: CN¥0.76 (vs CN¥0.77 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.14 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.20 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.77 (vs CN¥0.99 in FY 2019)

New 90-day low: CN¥18.98

Nanjing Well Pharmaceutical Group Co.,Ltd.(XSSC:603351) dropped from S&P Global BMI Index

New 90-day low: CN¥21.09

New 90-day low: CN¥22.58

Third quarter earnings released

New 90-day low: CN¥24.94

Nanjing Well Pharmaceutical Group Co.,Ltd. to Report Q3, 2020 Results on Oct 24, 2020

First half earnings released

New 90-day high - CN¥37.44

Nanjing Well Pharmaceutical Group Co.,Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령